Another study has depicted that PK of fexofenadine remained consistent in cystic fibrosis patients and age-mate healthy participants, but probenecid co-administration considerably augmented its Cmax due to OAT3 inhibition in the kidneys [18,74]. This evidence concerns the gene SLC22A8 and cystic fibrosis.